New Mercies: Ria Bos - Mercy Ships
In this episode, Ria shares how Mercy Ships finds patients for surgery, the hope that is offered each person, and a night she’ll never forget.
Source: mercyships.org
Page 3 - Patient Selection News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Patient Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Patient Selection Today - Breaking & Trending Today
Finding Light in the Darkness - Mercy Ships
Umu's birth came with an unexpected twist as she entered the world with a benign tumor growing from the side of her face and neck.
Source: mercyships.org
Late-breaking Data Show Esprit BTK Drug-eluting Resorbable Scaffold Reduces Chronic Limb-threatening Ischemia Progression Compared to the Standard of Care
Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty
Source: dicardiology.com
Peptide Receptor Radionuclide Therapy (PRRT) Industry Set to Surge to US$1.3 Billion by 2033 at an I
The Peptide Receptor Radionuclide Therapy (PRRT) Industry is on a trajectory of exceptional growth, with projections indicating a worth of US$ 591.83 million in 2023 and a substantial leap towards US$ 1,300 million by 2033. This robust expansion is driven by a promising Compound Annual Growth Rate (CAGR) of 8.2% exp...
Source: pharmiweb.com
CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023
- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispec
Source: yahoo.com